Commentary: Revised susceptibility breakpoints fear, loathing and good sgienge

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages 970-971

  Dudley, Michael N ^a   Ambrose, Paul G ^b   Jones, Ronald N ^c  

^a Rempex Pharmaceuticals   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; PENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; INFECTION CONTROL; KLEBSIELLA; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEUS MIRABILIS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE;

EID: 84891598748     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/inf.0b013e3182a1b8cd     Document Type: Note

References (16)

1. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Networks at the Center for Disease Control and Preventions, 2009-2010. Infect Control Hosp Epidmiol. 2013;34:1-14.
2. Braykov NP, Eber MR, Klein EY, et al. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol. 2013;34:259-268.
3. Snitkin ES, Zelazny AM, Thomas PJ, et al; NIAC Comparative Sequencing Program. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med. 2012;4:148rall6.
4. Boucher HW, Talbott GH, Benjamin DK, et al. 10 × '20 Progress-Development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1685-1694.
5. Dudley MN, Ambrose PG, Bhavnani S, et al; Antimicrobial Susceptibility Testing Subcommittee of the Clinical Laboratory Standards Institute. Background and rationale for revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis. 2013;56:1301-1309.
6. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008;14(suppl. 1):169-174.
7. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 23rd Informational Supplement (Document M-100;S23). Wayne, PA: Clinical Laboratory Standards Institute; 2013.
8. Rocephin (ceftriaxone sodium) for injection [US prescribing information]. San Francisco, CA: Genentech; 2010.
9. Thornsberry C, Jones RN, Barry AL, et al. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response. Rev Infect Dis. 1982;4(suppl):S316-S324.
10. Tamma PD, Wu H, Gerber JS, et al. Outcome of children with Enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: Do the revised breakpoints translate to improved patient outcomes? Pediatr Infect Dis J. 2013;32:965-969.
11. Dickinson JD, Kollef MH. Early and adequate antibiotic therapy in the treatment of severe sepsis and septic shock. Curr Infect Dis Rep. 2011;13:399-405.
12. Lee N-Y, Lee C-C, Huang W-H, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum betalac tarn ase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis. 2013;56:488495.
13. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy. Its not just for mice anymore. Clin Infect Dis. 2007;44:79-86.
14. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, et al. Pharmacokineticpharmacodynamic considerations in the design of hospital-acquired or ventilator-associated hospital pneumonia studies: Look before you leap! Clin Infect Dis. 2010;51(suppl 1):S103-S110.
15. Tamma PD, Powers JH. Do patient data really support the CLSI recommendation for lowering third-generation cephalosporin interpretive breakpoints? Clin Infect Dis. 2013;57:624-625.
16. Domenech-Sanchez A, Marinez-Martinez L, Hernandez-Alles S, et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother. 2003;47:3332-3335.